TB-500
Regulatory registry
- Context
- Research / no approved-treatment claim
- Reason / limits
- FDA identifies TB-500 as a specific thymosin beta-4 fragment and notes missing human exposure data.
- Last source review
- October 15, 2026
- Review scope
- FDA safety-risk source rechecked October 15, 2026. This is not an approval, treatment recommendation or fresh review of every purported-use claim.
- Clinical phase
- Unknown: no current trial-specific phase check is included in this registry.
- Registry NDC / manufacturer
- Unknown unless linked to a matched FDA package record below.
Research-only means this library makes no approved-treatment claim. Compounding context does not mean compounded-only, authorized for compounding, or legally available. Product-specific source limits control.
Regulatory sources
FDA shortage tracker
Approval context and shortage status are separate. An NDC identifies a package; it does not establish FDA approval or permission to compound.
UnknownUnknown: no exact single-substance FDA shortage record matched. Absence from the dataset is not proof of availability or approval.
Full dated shortage record · All compound tracker entries
Matched package records (0)
Records match a single exact active substance. Route and presentation are shown separately; a record does not apply to every product or preparation.
No exact matched package records. NDC and manufacturer: Unknown. No stock claim is made.
Observed change history (0)
Observed dates are when our sync saw a source state, not when a shortage started or ended. Unchanged daily checks do not add duplicate events.
No observed status changes yet.